Drugs / PDNO
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04885491 | May 2021 → Apr 2023 | COVID-19, pulmonary hypertension | Attgeno AB | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PDNO | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04885491 ↗ |
| Route | Intravenous | “PDNO administered as an i.v. infusion” NCT04885491 ↗ |